Ovarian cancer, labeled by the medical society as the deadliest form of gynecologic cancer, was presented with a rather optimistic prospect in March this year. Studies on an experimental vaccine and the drug Avastin (already on the market) have suggested that both may help slow down late-stage ovarian cancer. The findings were presented at the Society of Gynecologic Oncology in Chicago in April 2015.
Researchers found that including the vaccine in the standard treatment of advanced-stage ovarian cancer in women forestalled recurrence. The FANG vaccine is a type of immunotherapy for ovarian cancer. The other study showed that administering Avastin after both surgery and chemotherapy stalled the progression of the cancer, compared with surgery and chemotherapy alone.
As with any experimental therapy, the long-term effectiveness and safety of these two therapies are yet to be ascertained. However, the point to note is that the developmental pipeline for the ovarian cancer therapeutics market is teeming with possibilities and this could be the driving force of a currently restrained market, especially in Asia Pacific.
Even though late-stage drugs for ovarian cancer have displayed poor efficacy, the positive news is that there have been minimal but steady improvements during progression-free survival. Investigational drugs such as trebananib and olaparib have also demonstrated promising results, indicating a possible approval over the next few years. However, this too is likely to be marred by low market penetration owing to premium prices and minimal therapeutic efficacy.
Browse the full report : http://www.mrrse.com/ovarian-cancer-therapeutics
The major challenge that the ovarian cancer therapeutics market faces is trying to halt the rapid progression of the disease, and that too by means of personalized and targeted therapy. A new set of drugs being developed by Constellation Pharmaceuticals and Epizyme is hoping to tackle this exact challenge.
The American Cancer Society indicates that ovarian cancer is the fifth most common cause of death by cancer among women, with one in every 75 women at the risk of getting ovarian cancer. Compared to Europe and North America, Asia has a relatively lower incidence of ovarian cancer. In 2015, around 21,290 women in the U.S. alone will be diagnosed with ovarian cancer, close to 14,200 of which will die from the disease this year.
Scientists all over the world continue to study the genes that are responsible for familial ovarian cancer and increased research activities in this field are not only expected to yield new drugs for the prevention and treatment of ovarian cancer but are also estimated to boost the growth of the ovarian cancer therapeutics market.
A study conducted by MRRSE Research on the ovarian cancer therapeutics market maps the growth and development of the market in Asia Pacific. The report forecasts that the market is likely to grow at a slow rate of 5.1%, reaching a value of US$417.6 million by 2020. The Asia Pacific market for ovarian cancer therapeutics, according to MRRSE Research, is primarily driven by inflation and the rising prevalence of ovarian cancer.
Even though targeted therapies for the treatment of ovarian cancer lag significantly behind other types of cancers, continued interest in novel molecular targets could help put the ovarian cancer therapeutics market on track.
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Pathophysiology
2.1.1 Ovarian Cancer – A Group of Distinct Diseases
2.1.2 Ovarian Cancer is Highly Heterogenic with Multiple Mutations and Affected Signaling Pathways
2.2 Symptoms and Diagnosis
2.3 Risk Factors
2.3.1 Age
2.3.2 Inherited Genetic Mutations
2.3.3 Greater Number of Lifetime Ovulations
2.3.4 Weight
2.3.5 Previous Medical Conditions
2.4 Treatment Algorithm
2.4.1 Surgery
2.4.2 First-Line Chemotherapy
2.4.3 Maintenance Therapy
2.5 Recurrent Disease

3 Marketed Products
3.1 Carboplatin
3.2 Paclitaxel
3.3 Gemcitabine
3.4 Topotecan
3.5 Pegylated Liposomal Doxorubicin
3.6 Yondelis
3.7 Avastin

4 Product Pipeline
4.1 Overview of Pipeline by Phase and Route of Administration
4.2 Overview of Pipeline by Molecule Type, Mechanism of Action and Molecular Target
4.2.1 Molecular Targets in the Developmental Pipeline
4.3 Clinical Trials
4.3.1 Clinical Trial Duration
4.3.2 Clinical Trial Size
4.3.3 Failure Rate
4.3.4 Discussion
4.4 Late-Stage Drugs in Developmental Pipeline
4.4.1 Niraparib
4.4.2 Olaparib
4.4.3 Vargatef
4.4.4 Trebananib
4.4.5 Farletuzumab
4.4.6 Karenitecin
4.5 Discussion

Send An Enquiry : http://www.mrrse.com/enquiry/112

5 Market Forecasts
5.1 Asia-Pacific
5.1.1 Overview
5.1.2 Treatment Use Patterns and Revenues in Asia-Pacific Markets
5.2 India
5.2.1 Treatment Use Patterns
5.2.2 Annual Cost of Therapy
5.2.3 Market Forecast
5.3 China
5.3.1 Treatment Use Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Forecast
5.4 Japan
5.4.1 Treatment Use Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Forecast
5.5 Australia
5.5.1 Treatment Use Patterns
5.5.2 Annual Cost of Therapy
5.5.3 Market Forecast
5.6 Drivers and Barriers
5.6.1 Drivers
5.6.2 Barriers

6 Deals
6.1 Licensing Deals
6.1.1 Clovis Oncology Enters into Licensing Agreement with Pfizer for PF-01367338


Upcoming Report :
• Profenofos Market - Global Industry Expert Opinions Analysis, Emerging Opportunities, Market Size, Share, Growth Drivers, Market Trends, Statistics And Forecast 2015 – 2020 http://www.mrrse.com/profenofos-market
Profenofos is an organophosphorus insecticide which is used to kill pests that damage crop and thus, affects the overall agricultural productivity. Profenofos chemical name is 0-4-bromo-2- chlorophenyl Oethyl S-propyl phosphorothioate. The molecular weight of profenofos is approximately 373. Profenofos is used as an ovicide and larvicide in order to kill insects and larvae of various insects. Profenofos intoxication has resulted mainly due to the accumulation of acetylcholine at the nerve endings. Profenofos is an amber coloured liquid. Profenofos generally has a garlic-like odour. Profenofos has a boiling point of 110oC.
• Polyethylene Terephthalate (PET) Resin Market - Global Industry Expert Opinions Analysis, Emerging Opportunities, Market Size, Share, Growth Drivers, Market Trends, Statistics And Forecast 2015 – 2020
http://www.mrrse.com/polyethylene-terephthalate-resin-market
Polyethylene terephthalate (PET) is a thermoplastic polymer that belongs to the family of polyester. Polyethylene terephthalate resin was introduced for commercial use as textile fiber and film in 1953. Polyethylene terephthalate (PET) in its natural state is semi-crystalline colorless resin. Polyethylene terephthalate varies from semi rigid to rigid mainly on the basis of the method used for processing it. Polyethylene terephthalate is light weight in nature and has good gas barrier and alcohol barrier properties. PET becomes white when it is exposed to chloroform and other chemicals such as toluene. Polyethylene terephthalate is generally manufactured from terephthalic acid or dimethyl terephthalate and ethylene glycol.

About Us
Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. Headquartered in New York, U.S., MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.


Contact Us:
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
Email: [email protected]
Website: http://www.mrrse.com/
Blog: http://mrrse.blogspot.com/